Multicenter phase II trial to investigate safety and efficacy of an adjuvant therapy with gemcitabine and cetuximab in patients with R0 or R1 resected pancreatic cancer.

H Fensterer, Peter Barth(Philipps University of Marburg), U. Settmacher, B. Schupfner, Cornelia Brendel(Philipps University of Marburg), Ralf‐Dieter Hofheinz(University of Mannheim), Carmen Schade‐Brittinger, Udo Lindig(Jena University Hospital), Thomas M. Gress(Universitätsklinikum Gießen und Marburg), Esther Endlicher(University Hospital Regensburg), Detlef K. Bartsch(Philipps University of Marburg), J. Faß, Hans‐Helge Mueller, Marko Kornmann(University Hospital Ulm), M Ebert
Journal of Clinical Oncology
May 20, 2011
10.1200/jco.2011.29.15_suppl.4039
Cited by 2

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort
|The Lancet Diabetes & Endocrinology|2017|951
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
|New England Journal of Medicine|2012|863